COMP <GO>
TGTX vs MDGL // FORWARD P/E MULTIPLE
TG Therapeutics Inc. (NASDAQ) VS. Madrigal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: TGTX 7
— MDGL 3
▲ FORWARD P/E MULTIPLE LEADER: TGTX
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
forward-pe
16.7x
LAST: $431.16 (+0.19%) • MKT CAP: $9.94B
forward-pe
24.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. MDGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | MDGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | -29.70% | +41.70 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | -1.91% | +1.63 | TGTX | /fcf-yield <GO> |
| Operating Margin | 20.00% | -31.30% | +51.30 | TGTX | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -30.10% | +98.10 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 180.00% | -92.70 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 7.65 | +5.27 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.7 | 30.1 | +34.60 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.08 | -0.21 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 16.7x | 24.0x | -7.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.36B | $9.94B | -$578.3M | MDGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | MDGL REV | TGTX GROSS % | MDGL GROSS % | TGTX FCF | MDGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $958.4M | 83.7% | — | -$25.0M | -$190.0M |
| FY 2024 | $329.0M | $180.1M | 88.3% | 96.5% | -$40.6M | -$457.0M |
| FY 2023 | $233.7M | $1.07B | — | — | -$41.9M | -$324.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
MDGL // BETA 1.08